[go: up one dir, main page]

WO2024168241A3 - Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia - Google Patents

Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia Download PDF

Info

Publication number
WO2024168241A3
WO2024168241A3 PCT/US2024/015154 US2024015154W WO2024168241A3 WO 2024168241 A3 WO2024168241 A3 WO 2024168241A3 US 2024015154 W US2024015154 W US 2024015154W WO 2024168241 A3 WO2024168241 A3 WO 2024168241A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
hyperphosphatemia
compositions
stabilized
targeted therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/015154
Other languages
French (fr)
Other versions
WO2024168241A2 (en
Inventor
Tobias L. AGERVALD
Kenneth E. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University
Indiana University Bloomington
Original Assignee
Indiana University
Indiana University Bloomington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University, Indiana University Bloomington filed Critical Indiana University
Publication of WO2024168241A2 publication Critical patent/WO2024168241A2/en
Publication of WO2024168241A3 publication Critical patent/WO2024168241A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are novel modified humanized bioactive FGF23 fusion proteins, compositions comprising such fusion proteins, and methods for making such fusion proteins for the treatment of an individual with hyperphosphatemia. Also contemplated are methods for treating hyperphosphatemia in an individual.
PCT/US2024/015154 2023-02-10 2024-02-09 Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia Ceased WO2024168241A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363484284P 2023-02-10 2023-02-10
US63/484,284 2023-02-10

Publications (2)

Publication Number Publication Date
WO2024168241A2 WO2024168241A2 (en) 2024-08-15
WO2024168241A3 true WO2024168241A3 (en) 2025-05-08

Family

ID=92263543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/015154 Ceased WO2024168241A2 (en) 2023-02-10 2024-02-09 Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia

Country Status (1)

Country Link
WO (1) WO2024168241A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024168241A2 (en) * 2023-02-10 2024-08-15 The Trustees Of Indiana University Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
US20170226172A1 (en) * 2014-03-28 2017-08-10 New York University Fgf23 fusion proteins
US20200362015A1 (en) * 2014-12-04 2020-11-19 Novartis Ag Methods and compositions using klotho variant polypeptides
WO2024168241A2 (en) * 2023-02-10 2024-08-15 The Trustees Of Indiana University Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
US20170226172A1 (en) * 2014-03-28 2017-08-10 New York University Fgf23 fusion proteins
US20200362015A1 (en) * 2014-12-04 2020-11-19 Novartis Ag Methods and compositions using klotho variant polypeptides
WO2024168241A2 (en) * 2023-02-10 2024-08-15 The Trustees Of Indiana University Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMASHITA TETSUO, KONISHI MORICHIKA, MIYAKE AYUMI, INUI KEN-ICHI, ITOH NOBUYUKI: "Fibroblast Growth Factor (FGF)-23 Inhibits Renal Phosphate Reabsorption by Activation of the Mitogen-activated Protein Kinase Pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 31, 1 August 2002 (2002-08-01), US , pages 28265 - 28270, XP093311767, ISSN: 0021-9258, DOI: 10.1074/jbc.M202527200 *

Also Published As

Publication number Publication date
WO2024168241A2 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MY208144A (en) Preparation method for rejuvenated regenerative fibroblast and application thereof
EP2497478A3 (en) Oligosaccaride compositions and use thereof in the treatment of infection
MX2021007434A (en) Synthetic and recombinant collagen peptides having biological activity.
MXPA05004225A (en) Neutralizing antibodies against gdf-8 and uses therefor.
WO2003082212A3 (en) Method for treating cancer in humans
WO2019209965A3 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2024168241A3 (en) Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia
MX2023010711A (en) Phenalkylamines and methods of making and using the same.
MX2022015966A (en) Antibodies and methods for treating claudin-associated diseases.
MX2022002437A (en) Methods for production of human recombinant arginase 1 and uses thereof.
EP2258702A3 (en) Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors
WO2023122280A3 (en) Compositions and methods for treating skin defects
WO2019195714A8 (en) Methods and compositions for treating skin disease with recombinant microorganisms
WO2024191972A3 (en) Anti-lipocalin-2 antibodies and uses thereof
EP1401496A4 (en) Compositions and methods for treating hyperimmune response in the eye
WO2005034879A3 (en) Treatment of diseases involving erbb2 kinase overexpression
MX2025008431A (en) Il-12 fc fusion proteins
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2024238955A3 (en) Relaxin-2 fusion protein analogs and methods of using same
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2024191937A3 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases and/or disorders
WO2024155457A3 (en) Her2 targeting trispecific protein for treatment of cancer
WO2023034853A3 (en) Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof
WO2024220378A3 (en) Raav vector for the treatment of cox20 deficiency

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24754128

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE